Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs)

Molecular Simulation

Volumn 35, Issue 4, 2009, Pages 311-324

  Mihajlovic, Marija L ^a,b   Mitrasinovic, Petar M ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

ArgusLab 4.0; AScore; Influenza virus neuraminidase; Inhibitors

Indexed keywords

ARGUSLAB 4.0; ASCORE; BINDING AFFINITIES; BINDING MODES; INFLUENZA VIRUS; INFLUENZA VIRUS NEURAMINIDASE; INHIBITORS; PROTEIN STRUCTURES; STRUCTURE-BASED;

DOCKING; EXPERIMENTS;

BINDING ENERGY;

EID: 68149157302     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927020802430752     Document Type: Article

References (44)

1. B.R. Murphy and R.G. Webster, in Fields Virology, D.B.N. Fields, M. Knipe, and P. Howley, eds., Lippincott-Raven, Philadelphia, 1996, pp. 1397-1445.
2. World Health Organization, A Revision of the system of nomenclature for influenza viruses: a WHO memorandum, Bull. World Health Organ. 58 (1980), pp. 585-591.
3. J.D. Thompson, D.G. Higgins, and T.J. Gibson, Improved sensitivity of profile searches through the use of sequence weights and gap excision, Comput. Appl. Biosci. 10 (1994), pp. 19-29.
4. C. Bender, H. Hall, J. Huang, A. Klimov, N. Cox, A. Hay, V. Gregory, K. Cameron, W. Lim, and K. Subbarao, Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998, Virology 254 (1999), pp. 115-123.
5. World Health Organization, Global influenza program surveillance network. Evolution of H5N1 avian influenza viruses in Asia, Emerg. Infect. Dis. 11 (2005), pp. 1515-1521.
6. C. Kim, W. Lew, M. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M. Chen, D. Mendel, and C. Tai, et al., Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity, J. Am. Chem. Soc. 119 (1997), pp. 681-690.
7. M. von Itzstein, W. Wu, M. Pegg, J. Dyason, B. Jin, T. Phan, M. Smythe, H. White, S. Oliver, P. Colman, et al., Rational design of potent sialidase-based inhibitors of influenza virus replication, Nature 363 (1993), pp. 418-423.
8. A.C. Hurt, P. Selleck, N. Komadina, R. Shaw, L. Brown, and I.G. Barr, Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes, Antiviral Res. 73 (2007), pp. 228-231.
9. M. Baz, Y. Abed, and G. Boivin, Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir, Antiviral Res. 74 (2007), pp. 159-162.
10. L. Gillim-Ross and K. Subbarao, Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses? PLOS Medicine 4 (2007), pp. 226-228.
11. M.A. Rameix-Welti, F. Agou, P. Buchy, S. Mardy, J. Aubin, M. Véron, S. van der Werf, and N. Naffakh, Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir, Antimicrob. Agents Chemother 50 (2006), pp. 3809-3815.
12. R.G. Webster, M. Peiris, H. Chen, and Y. Guan, H5N1 outbreaks and enzootic influenza, Infect. Dis. 12 (2006), pp. 3-8.
13. J.N. Varghese and P.M. Colman, Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 22 Å resolution, J. Mol. Biol. 221 (1991), pp. 473-486.
14. J.N. Varghese, W.G. Laver, and P.M. Colman, Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution, Nature 303 (1983), pp. 35-40.
15. S. Singh, M.J. Jedrzejas, G.M. Air, M. Luo, W.G. Laver, and W.J. Brouillette, Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction, J. Med. Chem. 38 (1995), pp. 3217-3225.
16. C.L. White, M.N. Janakiraman, W.G. Laver, C. Philippon, A. Vasella, G.M. Air, and M. Luo, A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies, J. Mol. Biol. 245 (1995), pp. 623-634.
17. E.A. Sudbeck, M.J. Jedrzejas, S. Singh, W.J. Brouillette, G.M. Air, W.G. Laver, Y.S. Babu, S. Bantia, P. Chand, N. Chu, et al., Guanidinobenzoic acid inhibitors of influenza virus neuraminidase, J. Mol. Biol. 267 (1997), pp. 584-594.
18. R.J. Russell, L.F. Haire, D.J. Stevens, P.J. Collins, Y.P. Lin, G.M. Blackburn, A.J. Hay, S.J. Gamblin, and J.J. Skehel, The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design, Nature 443 (2006), pp. 45-49.
19. C. Sangma and S. Hannongbua, Structural information and computational methods used in design of neuraminidase inhibitors, Curr. Comput. Aided Drug Design 3 (2007), pp. 113-132.
20. P. Nimmanpipug, J. Jitonnom, C. Ngaojampa, S. Hannongbua, and V.S. Lee, A computational H5N1 neuraminidase model and its binding to commercial drugs, Mol. Simul. 33 (2007), pp. 487-493.
21. D-Q. Wei, Q-S. Du, H. Sun, and K-C. Chou, Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands, Biochem. Biophys. Res. Commun. 344 (2006), pp. 1048-1055.
22. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235-242.
23. (a) I. Muegge, The effects of small changes in protein structure on predicted binding modes of known inhibitors of influenza virus neuraminidase: PMF-Scoring in DOCK4, Med. Chem. Res. 9 (1999), pp. 490-500; (b) A.M. Abu Hammada, F.U. Afifia, and M.O. Taha, Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions, J. Mol. Graph. Model. 26 (2007), pp. 443-456; (c) L. Birch, C.W. Murray, M.J. Hartshorn, I.J. Tickle, and M.L. Verdonk, Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase, J. Comput. Aided Mol. Design 16 (2002), pp. 855-869; (d) C.W. Murray, C.A. Baxter, and A.D. Frenkel, The sensitivity of the results of molecular docking to induced fit effects: application to thrombin, thermolysin and neuraminidase, J. Comput. Aided Mol. Design 13 (1999), pp. 547-562; (e) M.R. Landon, R.E. Amaro, R. Baron, C.H. Ngan, D.Ozonoff, J.A. McCammon, and S. Vajda, Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble, Chem. Biol. Drug. Des. 71 (2008) pp. 106-116.
24. W.J. Brouillette, S. Bajpai, S. Ali, S. Velu, V. Atigadda, B. Lommer, J. Finley, M. Luo, and G. Air, Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents, Bioorg. Med. Chem. 11 (2003), pp. 2739-2749.
25. A.T. Baker, J.N. Varghese, W.G. Laver, G.M. Air, and P.M. Colman, Threedimensional structure of neuraminidase of subtype N9 from an avian influenza virus, Proteins 2 (1987), pp. 111-117.
26. A.R. Leach, B.K. Shoichet, and C.E. Peishoff, Prediction of protein-ligand interactions. Docking and scoring: successes and gaps, J. Med. Chem. 49 (2006), pp. 5851-5852.
27. E.M. Krovat, T. Steindl, and T. Langer, Recent advances in docking and scoring, Curr. Comput. Aided Drug Design 1 (2005), pp. 93-102.
28. V. Mohan, A.C. Gibbs, M.D. Cummings, E.P. Jaeger, and R.L. DesJarlais, Docking: successes and challenges, Curr. Pharm. Design 11 (2005), pp. 323-333.
29. M.A. Thompson, ArgusLab 4.0.1, Planaria Software LLC, Seattle, WA, http://www.arguslab.com
30. QuantumLead 3.3.0, Quantum Pharmaceuticals, Moscow, http:// q-pharm.com
31. H.J. Böhm, The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure, J. Comput. Aided Mol. Design 8 (1994), pp. 243-256.
32. A.N. Jain, Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities, J. Comput. Aided Mol. Design 10 (1996), pp. 427-440.
33. M.D. Eldridge, C.W. Murray, T.R. Auton, G.V. Paolini, and R.P. Mee, Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes, J. Comput. Aided Mol. Design 11 (1997), pp. 425-445.
34. R.D. Head, M.L. Smythe, T.I. Oprea, C.L. Waller, S.M. Green, and G.R. Marshall, VALIDATE: a new method for the receptor-based prediction of binding affinities of novel ligands, J. Am. Chem. Soc. 118 (1996), pp. 3959-3969.
35. H.J. Böhm, Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs, J. Comput. Aided Mol. Design 12 (1998), p. 309.
36. I. Muegge and Y.C. Martin, A general and fast scoring function for protein-ligand interactions: a simplified potential approach, J. Med. Chem. 42 (1999), pp. 791-804.
37. I. Muegge, Y.C. Martin, P.J. Hajduk, and S.W. Fesik, Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein, J. Med. Chem. 42 (1999), pp. 2498-2503.
38. R. Wang, Y. Gao, and L. Lai, SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex, J. Mol. Model. 4 (1998), pp. 379-394.
39. R. Wang, L. Lai, and S. Wang, Further development and validation of empirical scoring functions for structure-based binding affinity prediction, J. Comput. Aided Mol. Design 16 (2002), pp. 11-26.
40. N. Moitessier, P. Englebienne, D. Lee, J. Lawandi, and C.R. Corbeil, Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go, British J. Pharmacol. 153 (2008), pp. S7-S26.
41. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comp. Chem. 19 (1999), pp. 1639-1662.
42. M.J. Jedrzejas, S. Singh, W.J. Brouillette, G.M. Air, and M. Luo, A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase, Proteins 23 (1995), pp. 264-277.
43. Q-S. Du, S-Q. Wang, and K-C. Chou, Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus, Biochem. Biophys. Res. Commun. 362 (2007), pp. 525-531.
44. M.L. Mihajlovic and P.M. Mitrasinovic, Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV), Biophys. Chem. 136 (2008), pp. 152-158.